Peptide PilotPeptide Pilot
Download on the App Store

Comparison

Liraglutide vs Tirzepatide

Daily liraglutide alongside weekly tirzepatide — pace of dosing, receptor coverage, and how each fits a tracked log.

Download on the App StoreiPhone · Free to download
Field
Liraglutide
Tirzepatide
Category
GLP-1
GLP-1
Common alias
GLP-1 agonist (Saxenda, Victoza)
Dual GIP/GLP-1 (Mounjaro, Zepbound)
Example vial
6 mg + 3 mL BAC water
10 mg + 2 mL BAC water
Concentration
2.00 mg/mL
5.00 mg/mL
Example dose
1.2 mg
2.5 mg
Doses per week
7× / week
1× / week
Doses per vial (rounded down)
5
4
Approx vial duration
0.7 weeks
4.0 weeks

Liraglutide and Tirzepatide both show up in the same conversations, but they aren't interchangeable. The table above lays the vial math side by side so you can see how concentration, doses-per-vial, and weekly cadence actually compare. The sections below walk through what each one is, how each is studied, and how each shows up in a tracked log — in plain English, no recommendations.

Tiebreakers

Where Liraglutide and Tirzepatide actually diverge

LiraglutideTirzepatide
Cadence7/wk1/wk
Concentration on example2.00 mg/mL5.00 mg/mL
Math weeks per vial0.74.0
CategoryGLP-1GLP-1

Bolded values are the higher of the two on numeric rows. Same-value rows aren't a verdict — they're shared properties.

Liraglutide vs Tirzepatide: the actual decision

This pair is the cleanest illustration of how cadence and receptor coverage compound. Liraglutide is a daily, single-receptor GLP-1 agonist; tirzepatide is a weekly, dual GLP-1 and GIP agonist. Either one of those changes alone would meaningfully shift the trial weight-loss numbers — together they explain why tirzepatide's average loss in SURMOUNT-1 (about 22.5 percent at 72 weeks) sits roughly four times higher than liraglutide's pivotal weight-loss readouts at the same general timeframe.

Mechanism is the structural divide. Liraglutide hits GLP-1 only and has a half-life around 13 hours. Tirzepatide hits GLP-1 plus GIP and has a half-life that lets weekly dosing make sense. The GIP arm is the part most readers ask about — it is the receptor that distinguishes tirzepatide from every previously approved molecule in this class, and it is the chemistry behind both the larger weight loss numbers and the slightly different early-weeks tolerance pattern compared to GLP-1-only molecules.

Mechanism, cadence, and what shows up in a log

Logging the two molecules looks completely different in practice. Liraglutide is a daily ritual: same general window, same site rotation discipline, daily side-effect scoring during titration. Tirzepatide is a weekly calendar event with a longer tolerance arc per dose change. Pen versus vial geometry matters here too: liraglutide is most often administered from a pre-filled pen with fixed click increments, while tirzepatide in research-supplier form is reconstituted from a lyophilized vial and drawn into a U-100 insulin syringe.

Cost-per-dose math favors tirzepatide on the table above because its weekly cadence and higher per-dose milligrams stretch the example vial across more weeks. Real pharmacy prices vary, and the cost column should be read as a ratio rather than a budget number. The mg-to-units calculator linked below handles either molecule once your vial concentration is set, and the dose calculator shows how unit counts shift across the titration ladder for each.

Liraglutide vs Tirzepatide: the numbers, side by side

Start with what actually goes into a syringe. The example Liraglutide vial on this site reconstitutes 6 mg in 3 mL of bacteriostatic water — about 2.00 mg per mL, which yields roughly 5 doses at the 1.2 mg example and lasts about 0.7 weeks at 7 doses per week. The example Tirzepatide vial reconstitutes 10 mg in 2 mL (5.00 mg/mL), which yields about 4 doses at 2.5 mg and stretches roughly 4.0 weeks at 1 dose per week. Those numbers are the starting point most people forget to write down, and they decide everything downstream — refill timing, unit count on the syringe barrel, and whether a 30-mL bac-water bottle stretches across one vial or two.

Category context matters too. Both Liraglutide and Tirzepatide sit in the GLP-1 bucket, so the head-to-head questions readers bring here are usually about cadence, titration step size, and which of the two molecules logs more cleanly inside a longer protocol rather than a from-scratch category choice. Cadence helps frame the rest: Liraglutide is logged about 7× per week in the example schedule, Tirzepatide about 1×.

The single most-asked-about mistake on each page is worth surfacing here, because they rarely overlap. On the Liraglutide side: Failing to titrate the dose up slowly. On the Tirzepatide side: Reusing the unit count from a previous vial after switching to a new vial that was reconstituted with a different diluent volume. Both are the kind of thing a tracked log catches early and an untracked routine catches late.

Top Liraglutide question
What's the difference between Saxenda and Victoza?

Saxenda and Victoza contain the same active ingredient, Liraglutide. However, they are used for different purposes and at different maximum doses. Saxenda is generally used for weight management and has a higher target dose (3.0 mg), while Victoza is primarily used for blood sugar management in type 2 diabetes and has a lower target dose (1.8 mg).

Top Tirzepatide question
How is tirzepatide reconstituted?

By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.

The calculator pages linked below let you swap your own vial size, diluent volume, and dose into the same math — these example numbers exist so the comparison renders with concrete figures instead of placeholders.

Frequently asked questions about Liraglutide vs Tirzepatide

What's the difference between Saxenda and Victoza?
Saxenda and Victoza contain the same active ingredient, Liraglutide. However, they are used for different purposes and at different maximum doses. Saxenda is generally used for weight management and has a higher target dose (3.0 mg), while Victoza is primarily used for blood sugar management in type 2 diabetes and has a lower target dose (1.8 mg).
Why is Liraglutide injected daily instead of weekly?
Liraglutide was designed to last for about 13 hours in the body. A once-daily injection ensures that there is a stable and effective level of the peptide in your system throughout the day. Other GLP-1 agonists, like Semaglutide, were later engineered to last even longer, allowing for a once-weekly dosing schedule.
What are the commonly reported side effects?
The most frequently reported side effect of Liraglutide is nausea, especially when starting or increasing the dose. Other common side effects can include diarrhea, constipation, headache, or fatigue. These often decrease over time as the body adjusts to the peptide.
How is tirzepatide reconstituted?
By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.
How many units of tirzepatide are in 2.5 mg?
It depends on the concentration. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2.5 mg is exactly 50 units on a U-100 syringe. With 4 mL of diluent (2.5 mg per mL), the same dose is 100 units.
Why is tirzepatide dosed weekly?
Because its half-life is roughly five days, which keeps plasma levels stable on a once-weekly schedule. That long half-life is also why a single missed dose has less effect than missing a dose of a daily peptide.

Related on Peptide Pilot

Log Liraglutide and Tirzepatide side by side in the app

Download on the App StoreiPhone · Free · No credit card
Download on theApp Store→